{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T06:15:24Z","timestamp":1778393724678,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202208320088"],"award-info":[{"award-number":["202208320088"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto de Salud Carlos III;Fondo Europeo de Desarrollo Regional-FEDER)","award":["CP23\/00051"],"award-info":[{"award-number":["CP23\/00051"]}]},{"name":"Instituto de Salud Carlos III;Fondo Europeo de Desarrollo Regional-FEDER)","award":["FI21\/00003"],"award-info":[{"award-number":["FI21\/00003"]}]},{"name":"Instituto de Salud Carlos III;Fondo Europeo de Desarrollo Regional-FEDER)","award":["PI23\/00171"],"award-info":[{"award-number":["PI23\/00171"]}]},{"DOI":"10.13039\/501100013941","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Diabetes y Enfermedades Metab\u00f3licas Asociadas","doi-asserted-by":"publisher","award":["CB15\/00071"],"award-info":[{"award-number":["CB15\/00071"]}],"id":[{"id":"10.13039\/501100013941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2021 SGR 00857,2021 SGR 01211"],"award-info":[{"award-number":["2021 SGR 00857,2021 SGR 01211"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2017-SGR-1149"],"award-info":[{"award-number":["2017-SGR-1149"]}],"id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["MCIN\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["MCIN\/AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-IAHU-0011"],"award-info":[{"award-number":["ANR-23-IAHU-0011"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Federation Fran\u00e7aise de Cardiologie","award":["FFC \u2013 MARTINEZ \u2013 Dotation 2022"],"award-info":[{"award-number":["FFC \u2013 MARTINEZ \u2013 Dotation 2022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Plasma apolipoproteins are linked to cardiometabolic dysfunctions, but their potential as biomarkers for metabolic dysfunction-associated steatohepatitis (MASH) remains underexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Plasma levels of 14 apolipoproteins (apoA-I, A-II, A-IV, B100, C-I, C-II, C-III, D, E, F, H, J, L1, M) were quantified using liquid chromatography\u2013tandem mass spectrometry in a cross-sectional study of 148 individuals with obesity undergoing bariatric surgery. Based on liver histology, participants were categorized as non-MASH (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200994; no liver alterations or simple steatosis,\u2009\u2265\u20095% intrahepatic fat) or MASH (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200954; steatosis with ballooning and lobular inflammation, with or without fibrosis). Correlations with clinical and biochemical parameters were assessed via Spearman\u2019s rank correlation, and associations with MASH were evaluated using logistic regression. Incremental predictive value beyond established risk factors was assessed through likelihood ratio tests (LRT), net reclassification improvement (NRI), and integrated discrimination improvement (IDI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ApoC-III and apoL1 were significantly higher in MASH compared with non-MASH participants, while other apolipoproteins showed no group differences. Higher apoE, apoL1 and apoJ levels were associated with increased odds of MASH, independently of age and sex. Associations for apoL1 and apoJ remained significant after adjustment for diabetes, dyslipidemia, and hypertension, or for established MASH risk factors including insulin resistance, triglycerides, waist circumference, and the AST\/ALT ratio. LRT analyses showed that apoJ (\u0394Deviance\u2009=\u20094.085,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.043) and apoL1 (\u0394Deviance\u2009=\u20093.954,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047) each improved model fit, with their combination providing additional improvement (\u0394Deviance\u2009=\u20097.534,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.023). NRI analysis indicated that the combination of apoJ and apoL1 provided the largest improvement (NRI total\u2009=\u20090.39,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.026), mainly by correctly reclassifying non-MASH individuals (NRI non-event\u2009=\u20090.31,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0023). IDI was also greatest for the combination (IDI\u2009=\u20090.04,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.034), indicating enhanced discrimination between MASH and non-MASH individuals. In an external cohort, the elevation of plasma apoJ in MASH was consistently replicated, whereas apoL1, apoC-III, and apoE showed no such pattern.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma apoJ and apoL1 may serve as potential biomarkers for diagnosing MASH in individuals with obesity, independent of traditional risk factors. Further validation in larger cohorts and mechanistic studies is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12944-025-02733-0","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T12:19:14Z","timestamp":1760444354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ApoJ and apoL1 as novel determinants of MASH: a cross-sectional study"],"prefix":"10.1186","volume":"24","author":[{"given":"Zichun","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souad","family":"Najib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda A.","family":"N\u00fa\u00f1ez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda A.","family":"Mart\u00ednez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Garc\u00eda-Melgares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Viguerie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Rossell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Julve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika\u00ebl","family":"Croyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ars\u00eanio Rodrigues","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos M.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien J.","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelise","family":"Genoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda D.","family":"Frutos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Ramos-Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent O.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"2733_CR1","doi-asserted-by":"crossref","unstructured":"Haas JT, Francque S, Staels B. pathophysiology and mechanisms of nonalcoholic fatty liver disease. annual review of physiology. Annu Rev Physiol; 2016. p. 181\u2013205.","DOI":"10.1146\/annurev-physiol-021115-105331"},{"key":"2733_CR2","doi-asserted-by":"crossref","unstructured":"Younossi ZM. Non-alcoholic fatty liver disease \u2013 A global public health perspective. J Hepatology. 2019. p. 531\u201344.","DOI":"10.1016\/j.jhep.2018.10.033"},{"key":"2733_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.aohep.2020.03.001","volume":"19","author":"A Lonardo","year":"2020","unstructured":"Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol. 2020;19:359\u201366.","journal-title":"Ann Hepatol"},{"key":"2733_CR4","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.soard.2020.07.009","volume":"16","author":"S Frey","year":"2020","unstructured":"Frey S, Patouraux S, Debs T, Gugenheim J, Anty R, Iannelli A. Prevalence of NASH\/NAFLD in people with obesity who are currently classified as metabolically healthy. Surg Obes Relat Dis. 2020;16:2050\u20137.","journal-title":"Surg Obes Relat Dis"},{"key":"2733_CR5","doi-asserted-by":"crossref","unstructured":"Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest, 2019. p. 3978\u201389.","DOI":"10.1172\/JCI129186"},{"key":"2733_CR6","doi-asserted-by":"crossref","unstructured":"Berger D, Desai V, Janardhan S. Con: Liver Biopsy Remains the Gold Standard to Evaluate Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical Liver Disease. Clin Liver Dis (Hoboken); 2019. p. 114\u20136.","DOI":"10.1002\/cld.740"},{"key":"2733_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497\u2013509.","journal-title":"N Engl J Med"},{"key":"2733_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299\u2013310.","journal-title":"N Engl J Med"},{"key":"2733_CR9","doi-asserted-by":"crossref","unstructured":"Table: GLP-1 and GIP\/GLP-1 receptor agonists for chronic weight management. The Medical letter on drugs and therapeutics. Med Lett Drugs Ther; 2024.","DOI":"10.58347\/tml.2024.1708d"},{"key":"2733_CR10","doi-asserted-by":"crossref","unstructured":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia. 2024;67.","DOI":"10.1007\/s00125-024-06196-3"},{"key":"2733_CR11","doi-asserted-by":"crossref","unstructured":"Dominiczak MH, Caslake MJ. Apolipoproteins: Metabolic role and clinical biochemistry applications. Annals of Clinical Biochemistry. Ann Clin Biochem; 2011. p. 498\u2013515.","DOI":"10.1258\/acb.2011.011111"},{"key":"2733_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00004836-200308000-00017","volume":"37","author":"M Koruk","year":"2003","unstructured":"Koruk M, Cemil Sava\u015f M, Yilmaz \u00d6, Tay\u015fi S, Karakok M, G\u00fcndo\u01e7du C, et al. Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2003;37:177\u201382.","journal-title":"J Clin Gastroenterol"},{"key":"2733_CR13","doi-asserted-by":"publisher","first-page":"6676526","DOI":"10.1155\/2021\/6676526","volume":"2021","author":"H Huang","year":"2021","unstructured":"Huang H, Wang J, Xu L, Miao M, Xu C. Association between high-density lipoprotein cholesterol to apolipoprotein a-i ratio and nonalcoholic fatty liver disease: a cross-sectional study. Int J Endocrinol. 2021;2021:6676526.","journal-title":"Int J Endocrinol"},{"key":"2733_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jacl.2015.11.017","volume":"10","author":"MH Yang","year":"2016","unstructured":"Yang MH, Sung J, Gwak GY. The associations between apolipoprotein B, A1, and the B\/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. J Clin Lipidol. 2016;10:289\u201398.","journal-title":"J Clin Lipidol"},{"key":"2733_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.clnu.2024.10.007","volume":"43","author":"M Kouvari","year":"2024","unstructured":"Kouvari M, Valenzuela-Vallejo L, Guatibonza-Garcia V, Verrastro O, Axarloglou E, Mylonakis SC, et al. Apolipoprotein C-III in association with metabolic-dysfunction associated steatotic liver disease: a large, multicenter study. Clin Nutr. 2024;43:101\u20138.","journal-title":"Clin Nutr"},{"key":"2733_CR16","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/hep.32631","volume":"77","author":"A Deprince","year":"2023","unstructured":"Deprince A, Hennuyer N, Kooijman S, Pronk ACM, Baug\u00e9 E, Lienard V, et al. Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism. Hepatology. 2023;77:1287\u2013302.","journal-title":"Hepatology"},{"key":"2733_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/path.6330","volume":"264","author":"M\u00c1 N\u00fa\u00f1ez-S\u00e1nchez","year":"2024","unstructured":"N\u00fa\u00f1ez-S\u00e1nchez M\u00c1, Mart\u00ednez-S\u00e1nchez MA, Sierra-Cruz M, Lambertos A, Rico-Chazarra S, Oliva-Bolar\u00edn A, et al. Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease. Journal of Pathology. 2024;264:101\u201311.","journal-title":"Journal of Pathology"},{"key":"2733_CR18","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1210\/clinem\/dgae028","volume":"109","author":"M\u00c1 N\u00fa\u00f1ez-S\u00e1nchez","year":"2024","unstructured":"N\u00fa\u00f1ez-S\u00e1nchez M\u00c1, Mart\u00ednez-S\u00e1nchez MA, Mart\u00ednez-Montoro JI, Balaguer-Rom\u00e1n A, Murcia-Garc\u00eda E, Fern\u00e1ndez-Ruiz VE, et al. Lipidomic analysis reveals alterations in hepatic FA profile associated with MASLD stage in patients with obesity. J Clin Endocrinol Metab. 2024;109:1781\u201392.","journal-title":"J Clin Endocrinol Metab"},{"key":"2733_CR19","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/hep.25889","volume":"56","author":"P Bedossa","year":"2012","unstructured":"Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751\u20139.","journal-title":"Hepatology"},{"key":"2733_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412\u20139.","journal-title":"Diabetologia"},{"key":"2733_CR21","doi-asserted-by":"publisher","first-page":"jlr.D120000835","DOI":"10.1194\/jlr.D120000835","volume":"61","author":"V Blanchard","year":"2020","unstructured":"Blanchard V, Gar\u00e7on D, Jaunet C, Chemello K, Billon-Crossouard SS, Aguesse A, et al. A high-throughput mass spectrometry\u2013based assay for large-scale profiling of circulating human apolipoproteins. J Lipid Res. 2020;61:jlr.D120000835.","journal-title":"J Lipid Res"},{"key":"2733_CR22","doi-asserted-by":"crossref","unstructured":"De Nardo W, Lee O, Johari Y, Bayliss J, Pensa M, Miotto PM, et al. Integrated liver-secreted and plasma proteomics identify a predictive model that stratifies MASH. Cell Rep Med. 2025;6.","DOI":"10.1016\/j.xcrm.2025.102085"},{"key":"2733_CR23","unstructured":"R: The R Project for Statistical Computing. https:\/\/www.r-project.org\/."},{"key":"2733_CR24","doi-asserted-by":"crossref","unstructured":"Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. Diabetes Care; 2004. p. 1487\u201395.","DOI":"10.2337\/diacare.27.6.1487"},{"key":"2733_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-1-0716-0471-7_3","volume":"2138","author":"A Poljak","year":"2020","unstructured":"Poljak A, Duncan MW, Jayasena T, Sachdev PS. Quantitative assays of plasma apolipoproteins. Methods Mol Biol (Clifton, NJ). 2020;2138:49\u201381.","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"key":"2733_CR26","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1194\/jlr.P023697","volume":"53","author":"C Christoffersen","year":"2012","unstructured":"Christoffersen C, Benn M, Christensen PM, Gordts PLSM, Roebroek AJM, Frikke-Schmidt R, et al. The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles. J Lipid Res. 2012;53:2198\u2013204.","journal-title":"J Lipid Res"},{"key":"2733_CR27","doi-asserted-by":"crossref","unstructured":"Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology. 2010. p. 679\u201389.","DOI":"10.1002\/hep.23280"},{"key":"2733_CR28","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1053\/jhep.2002.32527","volume":"35","author":"M Charlton","year":"2002","unstructured":"Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002;35:898\u2013904.","journal-title":"Hepatology"},{"key":"2733_CR29","doi-asserted-by":"crossref","unstructured":"Zou Y, Zhong L, Hu C, Sheng G. Association between the alanine aminotransferase\/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study. Lipids in Health and Disease. 2020;19.","DOI":"10.1186\/s12944-020-01419-z"},{"key":"2733_CR30","doi-asserted-by":"publisher","first-page":"1457598","DOI":"10.3389\/fendo.2024.1457598","volume":"15","author":"Y Xuan","year":"2024","unstructured":"Xuan Y, Wu D, Zhang Q, Yu Z, Yu J, Zhou D. Elevated ALT\/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States. Front Endocrinol. 2024;15:1457598.","journal-title":"Front Endocrinol"},{"key":"2733_CR31","doi-asserted-by":"crossref","unstructured":"Gangadharan B, Bapat M, Rossa J, Antrobus R, Chittenden D, Kampa B, et al. Discovery of novel biomarker candidates for liver Fibrosis in Hepatitis C patients: A preliminary study. PLoS ONE. 2012;7.","DOI":"10.1371\/journal.pone.0039603"},{"key":"2733_CR32","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1073\/pnas.90.2.725","volume":"90","author":"BJ Aronow","year":"1993","unstructured":"Aronow BJ, Lund SD, Brown TL, Harmony JAK, Witte DP. Apolipoprotein J expression at fluid-tissue interfaces: potential role in barrier cytoprotection. Proc Natl Acad Sci U S A. 1993;90:725\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2733_CR33","doi-asserted-by":"crossref","unstructured":"Kujiraoka T, Hattori H, Miwa Y, Ishihara M, Ueno T, Ishii J, et al. Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. J Atheroscler Thromb. 2006.","DOI":"10.5551\/jat.13.314"},{"key":"2733_CR34","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.4103\/0366-6999.164983","volume":"128","author":"N Yang","year":"2015","unstructured":"Yang N, Qin Q. Apolipoprotein J: a new predictor and therapeutic target in cardiovascular disease? Chin Med J. 2015;128:2530\u20134.","journal-title":"Chin Med J"},{"key":"2733_CR35","doi-asserted-by":"crossref","unstructured":"Gil SY, Youn BS, Byun K, Huang H, Namkoong C, Jang PG, et al. Clusterin and LRP2 are critical components of the hypothalamic feeding regulatory pathway. Nat Commun. 2013;4.","DOI":"10.1038\/ncomms2896"},{"key":"2733_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13993-7","volume":"11","author":"JA Seo","year":"2020","unstructured":"Seo JA, Kang MC, Yang WM, Hwang WM, Kim SS, Hong SH, et al. Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity. Nat Commun. 2020;11:1\u201315.","journal-title":"Nat Commun"},{"key":"2733_CR37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.atherosclerosis.2015.06.003","volume":"241","author":"A Rull","year":"2015","unstructured":"Rull A, Mart\u00ednez-Bujidos M, P\u00e9rez-Cuellar M, P\u00e9rez A, Ord\u00f3\u00f1ez-Llanos J, S\u00e1nchez-Quesada JL. Increased concentration of clusterin\/apolipoprotein J (apoJ) in hyperlipemic serum is paradoxically associated with decreased apoJ content in lipoproteins. Atherosclerosis. 2015;241:463\u201370.","journal-title":"Atherosclerosis"},{"key":"2733_CR38","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1097\/HEP.0000000000000185","volume":"78","author":"S Duan","year":"2023","unstructured":"Duan S, Qin N, Pi J, Sun P, Gao Y, Liu L, et al. Antagonizing apolipoprotein J chaperone promotes proteasomal degradation of mTOR and relieves hepatic lipid deposition. Hepatology. 2023;78:1182\u201399.","journal-title":"Hepatology"},{"key":"2733_CR39","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1101\/gr.085647.108","volume":"19","author":"EE Smith","year":"2009","unstructured":"Smith EE, Malik HS. The apolipoprotein l family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions. Genome Res. 2009;19:850\u20138.","journal-title":"Genome Res"},{"key":"2733_CR40","doi-asserted-by":"crossref","unstructured":"Pays E. The Janus-faced functions of Apolipoproteins L in membrane dynamics. Cell Mol Life Sci. 2024;81.","DOI":"10.1007\/s00018-024-05180-9"},{"key":"2733_CR41","doi-asserted-by":"crossref","unstructured":"Adeva-Andany MM, Funcasta-Calder\u00f3n R, Fern\u00e1ndez-Fern\u00e1ndez C, Ameneiros-Rodr\u00edguez E, Vila-Altesor M, Castro-Quintela E. The metabolic effects of APOL1 in humans. Pflugers Archiv European Journal of Physiology. Pflugers Arch; 2023. p. 911\u201332.","DOI":"10.1007\/s00424-023-02821-z"},{"key":"2733_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1006\/geno.2001.6534","volume":"74","author":"NM Page","year":"2001","unstructured":"Page NM, Butlin DJ, Lomthaisong K, Lowry PJ. The human apolipoprotein L gene cluster: identification, classification, and sites of distribution. Genomics. 2001;74:71\u20138.","journal-title":"Genomics"},{"key":"2733_CR43","doi-asserted-by":"publisher","first-page":"25576","DOI":"10.1074\/jbc.272.41.25576","volume":"272","author":"PN Duchateau","year":"1997","unstructured":"Duchateau PN, Pullinger CR, Orellana RE, Kunitake ST, Naya-Vigne J, O\u2019Connor PM, et al. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem. 1997;272:25576\u201382.","journal-title":"J Biol Chem"},{"key":"2733_CR44","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1681\/ASN.2016040441","volume":"28","author":"K Shukha","year":"2017","unstructured":"Shukha K, Mueller JL, Chung RT, Curry MP, Friedman DJ, Pollak MR, et al. Most ApoL1 is secreted by the liver. J Am Soc Nephrol. 2017;28:1079\u201383.","journal-title":"J Am Soc Nephrol"},{"key":"2733_CR45","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/ATVBAHA.109.186031","volume":"29","author":"WS Davidson","year":"2009","unstructured":"Davidson WS, Silva RAGD, Chantepie S, Lagor WR, Chapman MJ, Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol. 2009;29:870\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2733_CR46","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1194\/jlr.P061598","volume":"57","author":"J Cubedo","year":"2016","unstructured":"Cubedo J, Padr\u00f3 T, Alonso R, Mata P, Badimon L. Apol1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia. J Lipid Res. 2016;57:1059\u201373.","journal-title":"J Lipid Res"},{"key":"2733_CR47","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1194\/jlr.M400304-JLR200","volume":"46","author":"TSE Albert","year":"2005","unstructured":"Albert TSE, Duchateau PN, Deeb SS, Pullinger CR, Cho MH, Heilbron DC, et al. Apolipoprotein L-I is positively associated with hyperglycemia and plasma triglycerides in CAD patients with low HDL. J Lipid Res. 2005;46:469\u201374.","journal-title":"J Lipid Res"},{"key":"2733_CR48","doi-asserted-by":"crossref","unstructured":"Nishimura K, Murakami T, Sakurai T, Miyoshi M, Kurahashi K, Kishi S, et al. Circulating Apolipoprotein L1 is associated with insulin resistance-induced abnormal lipid metabolism. Sci Rep. 2019;9.","DOI":"10.1038\/s41598-019-51367-7"},{"key":"2733_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12933-022-01452-5","volume":"21","author":"M Croyal","year":"2022","unstructured":"Croyal M, Wargny M, Chemello K, Chevalier C, Blanchard V, Bigot-Corbel E, et al. Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes. Cardiovasc Diabetol. 2022;21:21.","journal-title":"Cardiovasc Diabetol"},{"key":"2733_CR50","doi-asserted-by":"publisher","first-page":"e16200","DOI":"10.1111\/liv.16200","volume":"45","author":"G Mocciaro","year":"2025","unstructured":"Mocciaro G, George AL, Allison M, Frontini M, Huang-Doran I, Reiman F, et al. Oxidised apolipoprotein peptidome characterises metabolic dysfunction-associated steatotic liver disease. Liver Int. 2025;45:e16200.","journal-title":"Liver Int"},{"key":"2733_CR51","doi-asserted-by":"crossref","unstructured":"Bor\u00e9n J, Packard CJ, Taskinen MR. The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans. Front Endocrinol (Lausanne). Front Endocrinol (Lausanne); 2020.","DOI":"10.3389\/fendo.2020.00474"},{"key":"2733_CR52","doi-asserted-by":"crossref","unstructured":"Rehues P, Girona J, Guardiola M, Ozcariz E, Amig\u00f3 N, Rosales R, et al. ApoC-III proteoforms are associated with better lipid, inflammatory, and glucose profiles independent of total apoC-III. Cardiovasc Diabetol. 2024;23.","DOI":"10.1186\/s12933-024-02531-5"},{"key":"2733_CR53","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1194\/jlr.M400479-JLR200","volume":"46","author":"G Gerritsen","year":"2005","unstructured":"Gerritsen G, Rensen PCN, Kypreos KE, Zannis VI, Havekes LM, Van Dijk KW. ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression. J Lipid Res. 2005;46:1466\u201373.","journal-title":"J Lipid Res"},{"key":"2733_CR54","doi-asserted-by":"publisher","first-page":"17416","DOI":"10.1074\/jbc.M800756200","volume":"283","author":"CS Gangabadage","year":"2008","unstructured":"Gangabadage CS, Zdunek J, Tessari M, Nilsson S, Olivecrona G, Wijmenga SS. Structure and dynamics of human apolipoprotein CIII. J Biol Chem. 2008;283:17416\u201327.","journal-title":"J Biol Chem"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02733-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02733-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02733-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:02:42Z","timestamp":1760486562000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-025-02733-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2733"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02733-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6718852\/v1","asserted-by":"object"}]},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol was approved by the Ethics and Clinical Research Committees of the Virgen de la Arrixaca University Hospital (ref. number 2020\u20132-4-HCUVA; date: 31\/03\/2020). Informed consent to participate was signed by all participants and all of the reported investigations were carried out in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"319"}}